J Clin Oncol2023 Jul 10.
転移性ホルモン感受性前立腺癌におけるダロルタミド+アンドロゲン除去療法とドセタキセルの第III相ARASENS試験における病変量とリスクサブグループ別比較
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
Hussain M, Tombal B, Saad F, Fizazi K, Sternberg CN, Crawford ED, Shore N, Kopyltsov E, Kalebasty AR, Bögemann M, Ye D, Cruz F, Suzuki H, Kapur S, Srinivasan S, Verholen F, Kuss I, Joensuu H, Smith MR